Payment overview · 2025
General Payments
$405.68
18 reported records · 10 companies
Healthcare provider profile · identity verified
Ajit Singh, MD
Allopathic & Osteopathic Physicians|Internal Medicine · COCONUT CREEK, FL · NPI 1427008838
Verified facts
What the public records show
CMS Open Payments records show Ajit Singh, MD received $405.68 in general payments during 2025 across 18 reported records.
Abbott Laboratories accounted for 20.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Creon by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $82.39 | 20.3% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $79.44 | 19.6% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $51.87 | 12.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $38.34 | 9.4% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $31.08 | 7.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.68 | 7.6% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $29.23 | 7.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.42 | 7.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.90 | 4.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.33 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $405.68 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $82.39 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $81.10 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $79.44 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $38.34 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $31.08 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $30.68 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.42 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 26 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 578 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 370 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 329 | 74 |
| Losartan Potassium | Losartan Potassium | 225 | 42 |
| Omeprazole | Omeprazole | 203 | 31 |
| Metformin Hcl | Metformin Hcl | 199 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 198 | 29 |
| Lisinopril | Lisinopril | 191 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 174 | 32 |
| Famotidine | Famotidine | 173 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 165 | 29 |
| Gabapentin | Gabapentin | 161 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 160 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 157 | 27 |
| Levetiracetam | Levetiracetam | 156 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 153 | 33 |
| Donepezil Hcl | Donepezil Hcl | 142 | 20 |
| Memantine Hcl | Memantine Hcl | 126 | 17 |
| Carvedilol | Carvedilol | 116 | 32 |
| Simvastatin | Simvastatin | 107 | 17 |
| Furosemide | Furosemide | 104 | 20 |
| Eliquis | Apixaban | 102 | 27 |
| Trazodone Hcl | Trazodone Hcl | 95 | 18 |
| Finasteride | Finasteride | 79 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 68 | 22 |
| Alendronate Sodium | Alendronate Sodium | 65 | 12 |
| Bumetanide | Bumetanide | 64 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 14 |
| Lactulose | Lactulose | 62 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 62 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 60 | 13 |
| Glipizide | Glipizide | 60 | 15 |
| Mirtazapine | Mirtazapine | 59 | 14 |
| Nifedipine Er | Nifedipine | 58 | 18 |
| Risperidone | Risperidone | 58 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 56 | 11 |
| Tradjenta | Linagliptin | 55 | suppressed |
| Azithromycin | Azithromycin | 53 | 45 |
| Loperamide | Loperamide Hcl | 51 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 42 |
| Pregabalin | Pregabalin | 49 | suppressed |
| Atenolol | Atenolol | 48 | suppressed |
| Bupropion Xl | Bupropion Hcl | 47 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 47 | suppressed |
| Olanzapine | Olanzapine | 47 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 45 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 44 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 44 | suppressed |
| Ezetimibe | Ezetimibe | 43 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 42 | 11 |
| Valsartan | Valsartan | 42 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 41 | suppressed |
| Klor-Con M20 | Potassium Chloride | 41 | suppressed |
| Latanoprost | Latanoprost | 41 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 41 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 40 | suppressed |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Spironolactone | Spironolactone | 39 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 22 |
| Glipizide Er | Glipizide | 37 | suppressed |
| Aripiprazole | Aripiprazole | 36 | suppressed |
| Baclofen | Baclofen | 36 | suppressed |
| Allopurinol | Allopurinol | 35 | suppressed |
| Meloxicam | Meloxicam | 35 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 15 |
| Pradaxa | Dabigatran Etexilate Mesylate | 34 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 34 | 13 |
| Dorzolamide Hcl | Dorzolamide Hcl | 33 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 33 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | 14 |
| Creon | Lipase/Protease/Amylase | 31 | suppressed |
| Folic Acid | Folic Acid | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 29 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Novolin R | Insulin Regular, Human | 28 | suppressed |
| Procrit | Epoetin Alfa | 28 | suppressed |
| Budesonide | Budesonide | 27 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 27 | suppressed |
| Potassium Chloride | Potassium Chloride | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | 12 |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Xifaxan | Rifaximin | 25 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 24 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 22 | 11 |
| Prednisone | Prednisone | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 12 |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 11 |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Veo Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $405.68 · 18 records | Abbott Laboratories | Cologuard Collection Kit, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rystiggo, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error